{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T02:27:38Z","timestamp":1790044058047,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10120-021-01237-x","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T09:04:20Z","timestamp":1629795860000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)"],"prefix":"10.1007","volume":"25","author":[{"given":"Yoshikazu","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-7543","authenticated-orcid":false,"given":"Yu","family":"Sunakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Akamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"1237_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1237_CR2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23:1920\u20138.","journal-title":"Clin Cancer Res"},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543\u201352.","journal-title":"JAMA Oncol"},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","volume":"15","author":"S Champiat","year":"2018","unstructured":"Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria J-C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018;15:748\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1237_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2018.07.006","volume":"70","author":"J Fuentes-Antr\u00e1s","year":"2018","unstructured":"Fuentes-Antr\u00e1s J, Provencio M, D\u00edaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev. 2018;70:16\u201321.","journal-title":"Cancer Treat Rev"},{"key":"1237_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.trecan.2020.01.005","volume":"6","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Subbiah IM, Matos I, Garralda E, Menta AK, Ganeshan DM, et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact? Trends Cancer. 2020;6:181\u201391.","journal-title":"Trends Cancer"},{"key":"1237_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2217\/fon-2019-0167","volume":"15","author":"Y Sunakawa","year":"2019","unstructured":"Sunakawa Y, Inoue E, Matoba R, Kawakami H, Sato Y, Nakajima TE, et al. DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer. Future Oncol. 2019;15:2441\u20137.","journal-title":"Future Oncol"},{"key":"1237_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","volume":"20","author":"C Ferte","year":"2014","unstructured":"Ferte C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res. 2014;20:246\u201352.","journal-title":"Clin Cancer Res"},{"key":"1237_CR9","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1016\/j.ejca.2011.06.012","volume":"47","author":"C Gomez-Roca","year":"2011","unstructured":"Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer. 2011;47:2512\u20136.","journal-title":"Eur J Cancer"},{"key":"1237_CR10","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242\u201350.","journal-title":"Clin Cancer Res"},{"key":"1237_CR11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","volume":"22","author":"A Sasaki","year":"2019","unstructured":"Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793\u2013802.","journal-title":"Gastric Cancer"},{"key":"1237_CR12","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41416-020-0975-7","volume":"123","author":"T Hagi","year":"2020","unstructured":"Hagi T, Kurokawa Y, Kawabata R, Omori T, Matsuyama J, Fujitani K, et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. 2020;123:965\u201372.","journal-title":"Br J Cancer"},{"key":"1237_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605\u201311.","journal-title":"Ann Oncol"},{"key":"1237_CR14","doi-asserted-by":"publisher","first-page":"e000488","DOI":"10.1136\/esmoopen-2019-000488","volume":"4","author":"M Aoki","year":"2019","unstructured":"Aoki M, Shoji H, Nagashima K, Imazeki H, Miyamoto T, Hirano H, et al. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. ESMO Open. 2019;4:e000488.","journal-title":"ESMO Open"},{"key":"1237_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s10147-020-01810-x","volume":"26","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Yamada T, Sugaya A, Ueyama S, Yamamoto Y, Moriwaki T, et al. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden. Int J Clin Oncol. 2021;26:370\u20137.","journal-title":"Int J Clin Oncol"},{"key":"1237_CR16","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1111\/cas.13800","volume":"109","author":"S Kimbara","year":"2018","unstructured":"Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci. 2018;109:3583\u201390.","journal-title":"Cancer Sci"},{"key":"1237_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","volume":"122","author":"N Okada","year":"2020","unstructured":"Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, et al. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer. 2020;122:771\u20137.","journal-title":"Br J Cancer"},{"key":"1237_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/js.2017-00432","volume":"2","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc. 2018;2:241\u201351.","journal-title":"J Endocr Soc"},{"key":"1237_CR19","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"1237_CR20","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","volume":"23","author":"M Nishino","year":"2017","unstructured":"Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res. 2017;23:4671\u20139.","journal-title":"Clin Cancer Res"},{"key":"1237_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","volume":"58","author":"Q Wang","year":"2018","unstructured":"Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125\u201335.","journal-title":"Int Immunopharmacol"},{"key":"1237_CR22","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","volume":"26","author":"I Matos","year":"2020","unstructured":"Matos I, Martin-Liberal J, Garc\u00eda-Ruiz A, Hierro C, Ochoa de Olza M, Viaplana C, et al. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 11 criteria. Clin Cancer Res. 2020;26:1846\u201355.","journal-title":"Clin Cancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-021-01237-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01237-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:04:04Z","timestamp":1661299444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-021-01237-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s10120-021-01237-x","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"6 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Sunakawa reports grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharma, MSD, Daiichi Sankyo; and grants from Otsuka. Dr. Inoue reports personal fees from Bristol-Myers Squibb Japan, Pfizer, Nippontect systems, and RCR. Dr. Kito reports personal fees from Taiho Pharmaceutical, Chugai Pharma, Merck Biopharma, and Takeda. Dr. Takahashi reports personal fees from Takeda. Dr. Makiyama reports personal fees from Eli Lilly Japan, Taiho Pharmaceutical, Ono Pharma, Bristol-Myers Squibb Japan, and Daiichi Sankyo. Dr. Yasui reports personal fees from Daiichi Sankyo, Ono Pharma, Taiho Pharmaceutical, Bristol-Myers Squibb Japan, Chugai Pharma, Takeda, Eli Lilly Japan, TERUMO, Merck Biopharma, Yakult Honsha, and Bayer Yakuhin. Dr. Matoba reports stock of DNA chip Research Inc.. Dr. Kawakami reports grants and personal fees from Bristol-Myers Squibb Japan; personal fees from Ono Pharm. Dr. Nakajima reports grants from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Nippon Kayaku, Chugai Pharmaceutical, Sanofi, Taiho Pharmaceutical, Takeda, Eli Lilly Japan, Merck Biopharm, Daiichi Sankyo, Towa Pharmaceutical, Ono Pharm, MSD, Astellas Pharma Inc., Eisai, Solasia Pharma, Parexel International, A2 Healthecare, Mediscience Planning Inc., ICON Japan, EPS Holdings, Inc., and Japan Clinical Research Operations; personal fees from Sumitomo Dainippon Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Ono Pharm, Taiho Pharmaceutical, Takeda, Amgen Inc., Chugai Pharmaceutical, Sanofi, Novartis Japan, Nippon Kayaku, MSD, Eli Lilly Japan, Bayer Yakuhin, Pfizer, Daiichi Sankyo, Yakult Honsha, Nipro Co, Merck Biopharm, Celltrion Healthcare Japan, Teijin Pharma, and Sawai Pharmaceutical. Dr. Muro reports grants from Solasia Pharma, Merck Biopharm, Daiichi Sankyo, Parexel International, Pfizer, and MSD; grants and personal fees from Amgen, grants and personal fees from Ono Pharm, Sanofi, and Taiho Pharmaceutical; personal fees from AstraZeneca, Chugai Pharmaceutical, Takeda, Eli Lilly Japan, Bristol-Myers Squibb, and Bayer Yakuhin. Dr. Ichikawa reports grants from Takeda, Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Biopharm, Shionogi, and Ono Pharmaceutical; Merck Biopharm, Chugai Pharmaceutical, and Bayer Yakuhin. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}